Treatment modification in human immunodeficiency virus-infected individuals starting combination antiretroviral therapy between 2005 and 2008.
Data(s) |
2010
|
---|---|
Resumo |
BACKGROUND: Adverse effects of combination antiretroviral therapy (CART) commonly result in treatment modification and poor adherence. METHODS: We investigated predictors of toxicity-related treatment modification during the first year of CART in 1318 antiretroviral-naive human immunodeficiency virus (HIV)-infected individuals from the Swiss HIV Cohort Study who began treatment between January 1, 2005, and June 30, 2008. RESULTS: The total rate of treatment modification was 41.5 (95% confidence interval [CI], 37.6-45.8) per 100 person-years. Of these, switches or discontinuations because of drug toxicity occurred at a rate of 22.4 (95% CI, 19.5-25.6) per 100 person-years. The most frequent toxic effects were gastrointestinal tract intolerance (28.9%), hypersensitivity (18.3%), central nervous system adverse events (17.3%), and hepatic events (11.5%). In the multivariate analysis, combined zidovudine and lamivudine (hazard ratio [HR], 2.71 [95% CI, 1.95-3.83]; P < .001), nevirapine (1.95 [1.01-3.81]; P = .050), comedication for an opportunistic infection (2.24 [1.19-4.21]; P = .01), advanced age (1.21 [1.03-1.40] per 10-year increase; P = .02), female sex (1.68 [1.14-2.48]; P = .009), nonwhite ethnicity (1.71 [1.18-2.47]; P = .005), higher baseline CD4 cell count (1.19 [1.10-1.28] per 100/microL increase; P < .001), and HIV-RNA of more than 5.0 log(10) copies/mL (1.47 [1.10-1.97]; P = .009) were associated with higher rates of treatment modification. Almost 90% of individuals with treatment-limiting toxic effects were switched to a new regimen, and 85% achieved virologic suppression to less than 50 copies/mL at 12 months compared with 87% of those continuing CART (P = .56). CONCLUSIONS: Drug toxicity remains a frequent reason for treatment modification; however, it does not affect treatment success. Close monitoring and management of adverse effects and drug-drug interactions are crucial for the durability of CART. |
Identificador |
http://serval.unil.ch/?id=serval:BIB_FFDD9D2AEA04 isbn:1538-3679 (Electronic) pmid:20065200 doi:10.1001/archinternmed.2009.432 isiid:000273429200011 |
Idioma(s) |
en |
Fonte |
Archives of Internal Medicine, vol. 170, no. 1, pp. 57-65 |
Palavras-Chave | #AIDS-Related Opportunistic Infections/drug therapy; AIDS-Related Opportunistic Infections/epidemiology; Adenine/administration & dosage; Adenine/adverse effects; Adult; Anti-HIV Agents/administration & dosage; Anti-HIV Agents/adverse effects; Benzoxazines/administration & dosage; Benzoxazines/adverse effects; Deoxycytidine/administration & dosage; Deoxycytidine/adverse effects; Dideoxynucleosides/administration & dosage; Dideoxynucleosides/adverse effects; Drug Therapy, Combination; Female; HIV Infections/drug therapy; HIV Infections/epidemiology; Humans; Lamivudine/administration & dosage; Lamivudine/adverse effects; Lopinavir; Male; Middle Aged; Nevirapine/administration & dosage; Nevirapine/adverse effects; Oligopeptides/administration & dosage; Oligopeptides/adverse effects; Organophosphonates/administration & dosage; Organophosphonates/adverse effects; Proportional Hazards Models; Prospective Studies; Pyridines/administration & dosage; Pyridines/adverse effects; Pyrimidinones/administration & dosage; Pyrimidinones/adverse effects; Risk Factors; Switzerland/epidemiology; Zidovudine/administration & dosage; Zidovudine/adverse effects |
Tipo |
info:eu-repo/semantics/article article |